Purification and receptor binding properties of complexes between lutropin and monovalent antibodies against its alpha subunit

Conformation of the beta subunit of deglycosylated human chorionic gonadotropin in the interaction at receptor sites

The present study was performed to evaluate the relationship between the antagonist effect and the conformation of deglycosylated human chorionic gonadotropin (DGhCG) on the Leydig cell lutropin receptors. The maximum binding of [125I]DGhCG to anti-hCG beta antibody was decreased by 50%, while its binding profile to anti-hCG, anti-DGhCG and anti-hCG alpha antibodies remained unchanged, suggesting conformational changes in the beta subunit of DGhCG. However, the association of [125I]DGhCG to the binding sites of the receptors was much faster than that of [125I]hCG, and the ligand reached the binding equilibrium at 4 and 37 degrees C for 3 h and 15-30 min, respectively. Thus, the conformational changes in the beta subunit were not accompanied by loss of its receptor binding ability. The agonist properties of DGhCG which was bound to the receptors was fully restored by the addition of anti-hCG beta subunit antibody, while anti-hCG or anti-DGhCG restored only about 30% of the full agonist activity. This was probably due to a change of the conformation of the beta subunit to make it similar to that of the intact hormone. This restoration caused by anti-hCG beta was partially prevented by anti-hCG alpha. These facts indicate that some conformational change only in the beta subunit, not in the alpha subunit, of the deglycosylated hormone bound to the receptors is essential for the restoration of agonist properties.

Probing the receptor-interaction of glycoprotein hormones with monoclonal antibodies

Having recently analyzed with monoclonal antibodies (MCA) the immunologic surface of human chorionic gonadotropin (hCG) as consisting of 9 distinct epitopes exposed on the molecule in a characteristic topographical manner (Schwarz, S., Berger, P., and Wick, G., Endocrinology 118, 189-197, 1986) we now attempted to confirm this result on a more general basis, e.g. by incorporating MCA that were just recently obtained and previously not included. What we were, however, interested most was the question whether the tentative model of the epitope map of hCG could represent a "target" with which hCG-related hormones such as LH, FSH, and TSH (the family of glycoprotein hormones, GPH) would (partially) match. Indeed, repeating various immunizations with GPH of human as well as animal origin revealed a remarkable reproducibility in terms of several anticipated epitope specificities of MCA. This indicates that MCA can be regarded as reliable probes for mapping epitopes and, as we have presumed, of receptor interaction domains of GPH as well. Extending the originally used 2-site MCA binding exclusion approach by an interspecies crossreactivity (Xr) analysis we now are able to refine our epitope model of hCG such that 2 additional epitopes were found which were not previously resolvable. Most surprisingly, two of 5 epitopes on the alpha subunit were now also detected on various non-human GPH, which is in striking contrast to a seemingly well established dogma. Yet all five alpha epitopes of hCG are present on hLH, hFSH, and hTSH as well and arranged in the same spatial relationship to each other as on hCG. Even the 2 conformational epitopes and their close topographical relationship to the alpha-epitopes appear to be remarkably conserved on all human GPH. Among the beta-epitopes we have found one that is not shared by hLH and that - surprisingly - is not the C-terminal peptide (CTP) by which hLH differs from hCG. On the basis of this refined epitope map a way was paved along which it should be feasible to elucidate the sterical relationship of the epitopes to the receptor interaction domain(s) of hCG. To this end the MCA were tested in principally two ways: first, as to which of the 11 MCA with different epitope specificities would be able (or not) to inhibit by preincubation the binding of radiolabeled hCG (or hLH, respectively) to rat testis LH/hCG receptors? Secondly (and inversely) which of the 11 epitopes of hCG would still be accessible to binding by radiolabeled MCA when the (unlabeled) hormone is bound to the receptor?(ABSTRACT TRUNCATED AT 400 WORDS)

Preferential masking by the receptor of immunoreactive sites on the alpha subunit of human choriogonadotropin

125I-Labeled human choriogonadotropin (125I-hCG) bound to rat ovarian receptor was solubilized in Triton X-100. By using increasing concentrations of nine different antisera specific for the individual subunits of human choriogonadotropin (hCG), free 125I-hCG or 125I-hCG-receptor complex was precipitated by double-antibody technique. The ability of any antiserum to bind to the hormone-specific beta subunit was not affected by hCG binding to receptor, suggesting that this subunit is not directly involved with the receptor in the final state of the hormone-receptor complex. In contrast, every antiserum specific for the alpha subunit was dramatically inhibited in binding to the solubilized 125I-hCG-receptor complex. These results suggest that the alpha subunit directly interacts with the receptor, thereby masking immunoreactive sites normally available on the free hormone. Because a number of reports describe binding activity of high concentrations of immunopurified beta subunits of hCG, we propose a two-step model for the binding of hCG to receptor and postulate separate and distinct roles for the subunits. We propose that the binding of hCG to the receptor involves a specific low-affinity initial interaction of the beta subunit with the receptor that activates a second site for the high-affinity binding of alpha subunit and stabilization of the hormone-receptor complex.